- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05324436
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
January 17, 2025 updated by: Bristol-Myers Squibb
Special Drug Use Investigation (Survey) of Yervoy and Opdivo Combination Therapy in Patients With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 162-0822
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
The study population will consist of participants with unresectable advanced/recurrent Malignant Pleural Mesothelioma (MPM) who will start the combination therapy for the first time under daily routine practice in Japan.
Description
Inclusion Criteria:
- Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert
Exclusion Criteria:
- Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
- Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cohort 1
Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Adverse Events (AEs)
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to onset of serious adverse events (SAEs)
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to onset of AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to resolution of AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Time to resolution of SAEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - Non-serious AE
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - SAE
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of AEs leading to interruption of treatment
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of SAEs leading to interruption of treatment
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of AEs leading to treatment discontinuation
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Incidence of SAEs leading to treatment discontinuation
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Outcome of reported AEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Outcome of reported SAEs
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality
Time Frame: Up to 6 Months
|
Up to 6 Months
|
|
Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality
Time Frame: Up to 6 Months
|
Up to 6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2022
Primary Completion (Actual)
June 30, 2023
Study Completion (Actual)
June 30, 2023
Study Registration Dates
First Submitted
March 16, 2022
First Submitted That Met QC Criteria
April 5, 2022
First Posted (Actual)
April 12, 2022
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 17, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA209-6AF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.